UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/517,423	03/10/2005	Albert Duranton	122005	2517	
25944 OLIFF & BER	7590 09/10/2007 RRIDGE PLC		EXAMINER		
P.O. BOX 19928			KUDLA, JOSEPH S		
ALEXANDRI	A, VA 22320		ART UNIT	PAPER NUMBER	
			1609		
			MAIL DATE	DELIVERY MODE	
			09/10/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
•	10/517,423	DURANTON ET AL.	
Office Action Summary	Examiner	Art Unit	<del></del>
	Joseph S. Kudla	1609	
The MAILING DATE of this communication app	· · · · · · · · · · · · · · · · · · ·	1	
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO  36(a). In no event, however, may a reply be til  7ill apply and will expire SIX (6) MONTHS from  cause the application to become ABANDONE	N. mely filed the mailing date of this communication ED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 08 De	ecember 2004		
	action is non-final.		
3) Since this application is in condition for allowar		osecution as to the merits is	2
closed in accordance with the practice under E	•		•
Disposition of Claims	,		
4)⊠ Claim(s) <u>1-43</u> is/are pending in the application.			
4a) Of the above claim(s) is/are withdraw			
5) Claim(s) is/are allowed.	With total consideration.		
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>1-43</u> are subject to restriction and/or e	election requirement.		
Application Papers	·		
	_		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) acce		Eveniner	
Applicant may not request that any objection to the	· · · · · · · · · · · · · · · · · · ·		
Replacement drawing sheet(s) including the correcti			4)
11) The oath or declaration is objected to by the Ex		•	1).
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign	priority under 25 H.C.C. \$ 440/-	\	
a) ☐ All b) ☐ Some * c) ☐ None of:	priority under 55 0.5.C. § 119(a	)-(a) or (i).	
1. Certified copies of the priority documents	s have been received		
2. Certified copies of the priority documents		ion No	
3.☐ Copies of the certified copies of the prior	* *		
application from the International Bureau			
* See the attached detailed Office action for a list of	of the certified copies not receive	ed.	
Attachment(s)	•		
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	ate	
Information Disclosure Statement(s) (PTO/SB/08)     Paper No(s)/Mail Date	5) Notice of Informal F	atent Application	
•			

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-15 and 19-26, drawn to a composition comprising taurine and/or hypotaurine and/or salts thereof that are acceptable in an oral composition, for the preparation of an oral composition that is useful for treating and preventing aging of the pilosebaceous unit and/or alopecia.

Group II, claims 16-18, drawn to a composition comprising polyphenol(s) chosen from flavonols, anthocyanins, flavanols, proanthocyanidins and flavanones, and stilbenes. and/or of fatty acid(s) chosen from n-6 and n-3 essential polyunsaturated fatty acids, containing between 18 and 22 carbon atoms, and also esters thereof, and mixtures thereof, and/or of an extract comprising the same, for the preparation of an oral composition that is useful for treating or preventing disorders of the pilosebaceous unit. Application/Control Number: 10/517,423

Art Unit: 1609

Group III, claims 27-29, 31-32 and 36-38, drawn to a composition for oral absorption, comprising, as active agent, at least 0.05% to 80% by weight of taurine and/or hypotaurine and/or salts thereof acceptable for oral absorption and an excipient, said composition being free of vitamin C.

Group IV, claims 30 and 33-34, drawn to a composition for oral absorption, characterized in that it comprises at least one polyphenol chosen from flavonols, anthocyanins, flavanols, proanthocyanidins and flavanones, and stilbenes, and/or a fatty acid chosen from n-6 and n-3 essential polyunsaturated fatty acid(s), containing between 18 and 22 carbon atoms, and also esters thereof, and mixtures thereof, and/or an extract comprising the same, in combination with taurine and/or hypotaurine and/or salts thereof acceptable for oral absorption and, where appropriate, an excipient.

Group V, claim 35, drawn to a composition for oral absorption, characterized in that it comprises 0.01% to 30% by weight of taurine and/or hypotaurine and/or acceptable salts thereof, in combination with 0.01% to 10% by weight of fatty acids.

Group VI, claims 39-41, drawn to a method for treating and preventing aging of the hair and/or alopecia via the oral administration of taurine and/or hypotaurine and/or acceptable salts thereof.

Art Unit: 1609

Group VII, claims 42-43, drawn to a method for treating and preventing disorders of the pilosebaceous unit via the oral administration of at least one fatty acid, one polyphenol or an extract comprising the same, optionally in combination with taurine and/or hypotaurine and/or acceptable salts thereof.

2. The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: There is no special technical feature in the instant claim set.

The technical feature that applicant states in claim 1 is a composition comprising taurine and/or hypotaurine and/or salts thereof that are acceptable in an oral composition that is useful for treating and preventing aging of the pilosebaceous unit and/or alopecia. Claim 16 discloses a composition comprising polyphenol(s) and/or of fatty acid(s) and also esters thereof, and mixtures thereof, and/or of an extract comprising the same, for the preparation of an oral composition that is useful for treating or preventing disorders of the pilosebaceous unit. Claims 1 and 16 do not share a special technical feature, therefore; the claims lack unity.

Applicant is required to elect a group to be examined on the merits.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Application/Control Number: 10/517,423

Art Unit: 1609

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph S. Kudla whose telephone number is (571) 270-3288. The examiner can normally be reached on 9am-5pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker can be reached on (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JK

MICHAEL MELLER
PRIMARY EXAMINER